CClinicalTrials.gg
CompletedNCT07722416Updated Jul 23, 2026

Postoperative Pain After OCT or EDTA Irrigation in Regenerative Endodontic Treatment

An interventional study of Regenerative Endodontic Treatment Using Different Irrigation Solutions in Apical Periodontitis and Endodontic Disease, sponsored by TC Erciyes University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 8 Years to 16 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by TC Erciyes University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Oct 2025, registered Jul 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
8 Years to 16 Years
Sex
All
01

Study summary

This randomized clinical trial evaluated the effect of two different irrigation solutions on postoperative pain following regenerative endodontic treatment of necrotic immature permanent teeth with apical periodontitis. Participants were randomly allocated to receive either 0.1% octenidine dihydrochloride (OCT) or 17% ethylenediaminetetraacetic acid (EDTA) during regenerative endodontic treatment.

A total of 40 patients aged 9 to 16 years were included and allocated to the two intervention groups in a 1:1 ratio. Postoperative pain was recorded using a 0-100 numerical rating scale at 6, 12, and 24 hours and daily from the second through the seventh postoperative day. Analgesic use and the occurrence of flare-up were also evaluated.

Read the detailed description

Necrotic immature permanent teeth with apical periodontitis present a clinical challenge because incomplete root development is associated with thin dentinal walls, an open apex, and an increased risk of root fracture. Regenerative endodontic treatment is a biologically based procedure that aims to control intracanal infection, promote healing of the periapical tissues, and allow continued root development.

Successful regenerative endodontic treatment requires effective root canal disinfection while preserving an environment that supports the survival and activity of stem cells from the apical papilla. Ethylenediaminetetraacetic acid (EDTA) is commonly used in regenerative procedures because of its chelating properties, its ability to modify the dentin surface, and its potential to promote the release of dentin-derived bioactive molecules. Octenidine dihydrochloride (OCT) is a broad-spectrum antiseptic that has demonstrated antimicrobial activity and potentially favorable biological effects on dental-derived stem cells. However, clinical evidence regarding the use of OCT during regenerative endodontic treatment remains limited.

This prospective, participant-blinded, parallel-group randomized clinical trial included 40 systemically healthy patients aged 9 to 16 years who had a necrotic immature permanent tooth with apical periodontitis. Eligible teeth had Cvek stage 2 or 3 root development and a baseline Periapical Index score between 2 and 4. Each participant contributed one tooth to the study.

Participants were randomly assigned in a 1:1 ratio to one of two irrigation groups:

  1. The OCT group received 0.1% octenidine dihydrochloride.
  2. The EDTA group received 17% ethylenediaminetetraacetic acid.

Regenerative endodontic treatment was performed in two visits. During the first visit, the root canal was initially irrigated with 1.5% sodium hypochlorite. The allocated OCT or EDTA solution was then applied and ultrasonically activated. Calcium hydroxide was placed as an intracanal medicament, and the access cavity was temporarily sealed.

The second visit was performed approximately two weeks later. After removal of the intracanal medicament, the root canal was irrigated again according to the allocated protocol, and the irrigant was ultrasonically activated. Apical bleeding was induced to create an intracanal blood clot. Biodentine was placed over the blood clot as a coronal barrier, and the tooth was permanently restored with resin composite.

The primary outcome was postoperative pain intensity, which was recorded using a 0-100 numerical rating scale at 6, 12, and 24 hours and daily from day 2 through day 7 after the second treatment visit. Secondary outcomes included analgesic consumption and the occurrence of flare-up, defined as severe postoperative pain and/or swelling requiring an unscheduled clinical visit.

02

Conditions studied

  • Apical Periodontitis
  • Endodontic Disease

Keywords

  • apical periodontitis
  • immature permanent teeth
  • octenidine dihydrochloride
  • postoperative pain
  • regenerative endodontic treatment
03

In context

Periapical Periodontitis

246 studies on the registry are indexed under Periapical Periodontitis; 64 are open to participants now.

This study's enrollment of 40 is below the median of 60 across 211 interventional studies indexed under Periapical Periodontitis.

Browse Periapical Periodontitis studies →

Lead sponsor

TC Erciyes University is the lead sponsor of 341 studies on the registry; 76 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Systemically healthy status classified as American Society of Anesthesiologists class I;
  • An immature permanent tooth with pulp necrosis and apical periodontitis;
  • Cvek stage 2 or 3 root development;
  • Preoperative pain below 40 on a 0-100 numerical rating scale (NRS);
  • A baseline Periapical Index (PAI) score between 2 and 4;
  • A tooth considered restorable and suitable for RET; and
  • Willingness of the participant and legal representative to comply with postoperative assessment and follow-up requirements.

Exclusion criteria

Exclusion Criteria:

  • systemic disease
  • bruxism or another parafunctional habit
  • had used analgesics within 12 hours before treatment
  • severe root canal curvature
  • vertical root fracture
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
40 participants (actual)

Study arms

  • Active comparator
    17% Ethylenediaminetetraacetic Acid (EDTA)

    Participants in this arm received standardized two-visit regenerative endodontic treatment. During both treatment visits, 20 mL of 17% ethylenediaminetetraacetic acid (EDTA) was applied to the root canal for 5 minutes and ultrasonically activated for 1 minute. Sodium hypochlorite, calcium hydroxide intracanal medication, induction of apical bleeding, placement of a Biodentine coronal barrier, and permanent restoration were standardized for both study groups.

    Other: Regenerative Endodontic Treatment Using Different Irrigation Solutions

  • Active comparator
    0.1% Octenidine Dihydrochloride (OCT)

    Participants in this arm received standardized two-visit regenerative endodontic treatment. During both treatment visits, 20 mL of 0.1% octenidine dihydrochloride (OCT) was applied to the root canal for 5 minutes and ultrasonically activated for 1 minute. Sodium hypochlorite, calcium hydroxide intracanal medication, induction of apical bleeding, placement of a Biodentine coronal barrier, and permanent restoration were standardized for both study groups.

    Other: Regenerative Endodontic Treatment Using Different Irrigation Solutions

Interventions

  • OtherRegenerative Endodontic Treatment Using Different Irrigation Solutions

    Regenerative endodontic treatment was performed using either 0.1% octenidine dihydrochloride (OCT) or 17% ethylenediaminetetraacetic acid (EDTA) as the allocated irrigation solution. In both groups, 20 mL of the assigned irrigant was applied for 5 minutes during each treatment visit and ultrasonically activated for 1 minute.

06

What researchers measure

Primary outcomes

  1. Postoperative Pain Intensity Measured Using a Numerical Rating Scale

    Postoperative pain intensity was self-recorded by participants using a numerical rating scale ranging from 0 to 100, where 0 indicated no pain and 100 indicated the worst pain imaginable. Higher scores indicated greater postoperative pain intensity. Pain scores were recorded after the second regenerative endodontic treatment visit.

    Time frame: At 6, 12, and 24 hours and daily from Day 2 through Day 7 after the second treatment visit

Secondary outcomes

  1. Postoperative Analgesic Consumption

    Participants were instructed to use paracetamol only when postoperative pain persisted. A dose of 250 to 500 mg was recommended according to the participant's age and body weight. The number of paracetamol tablets taken at each assessment time was recorded as 0, 1, or 2. Higher values indicated greater analgesic consumption.

    Time frame: At 6, 12, and 24 hours and daily from Day 2 through Day 7 after the second treatment visit

07

Study locations

1 site
  • Erciyes Üniversitesi Diş Hekimliği Fakültesi
    Kayseri, Kayseri 38039, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07722416
Lead sponsor
TC Erciyes University
Responsible party
Busranur Yavuz (ARŞ.GÖR, TC Erciyes University) — Principal investigator
First posted
Jul 23, 2026
Start date
Oct 1, 2025
Primary completion
May 8, 2026
Completion
May 8, 2026
Last update
Jul 23, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion